Comparison of Two Dosing Regimens of GW433908/Ritonavir Versus Lopinavir/Ritonavir for 48 Weeks in HIV Patients Who Have Taken Protease Inhibitors and Experienced Virological Failure
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00025727
Recruitment Status : Unknown
Verified June 2002 by NIH AIDS Clinical Trials Information Service. Recruitment status was: Active, not recruiting
The purpose of this study is to test 2 different dosing regimens of GW433908/ritonavir (RTV) versus lopinavir (LPV)/RTV when each is given with 2 active reverse transcriptase inhibitors (RTIs), in patients who have taken anti-HIV drugs without success.
Patients will receive 2 dosing regimens of GW433908/RTV or LPV/RTV, in combination with 2 active RTIs, after failing their first or second protease inhibitor-containing regimen. Patients are required to be on therapy at time of screening and must remain on this therapy until Day 1.
A Phase III, Randomized, Multicenter, Parallel Group, Open-Label, Three Arm Study to Compare the Efficacy and Safety of Two Dosing Regimens of GW433908/Ritonavir (700mg/100mg Twice Daily or 1400mg/200mg Once Daily) Versus Lopinavir/Ritonavir (400mg/100mg Twice Daily) for 48 Weeks in Protease Inhibitor Experienced HIV-Infected Adults Experiencing Virological Failure
Study Start Date :
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
13 Years and older (Child, Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients may be eligible for this study if they:
Have a viral load of 1,000 or more copies/ml.
Have taken protease inhibitors (PIs).
Have taken PI drugs for at least 12 straight weeks and have had virologic failure on the PIs.
Are now taking antiretroviral therapy.
Are male or female and are at least 13 years old (or 18 if local requirement) and can provide consent from parent or guardian if under 18.
Are females unable to have children or, if are able to have children, are not pregnant and agree to use approved birth control.
Patients will not be eligible for this study if they:
Have taken APV or LPV for more than 1 week.
Have taken tenofovir disoproxil fumarate (TDF) or adefovir.
Have taken more than 2 PIs.
Are unable to take 2 active RTIs, as specified by the study.
Have an active CDC Category C disease.
Have certain abnormal laboratory tests.
Are pregnant or breast-feeding.
Have a serious health problem (e.g., diabetes, heart problems, hepatitis) that might risk the safety of the patient.
Have a history of significant kidney or bone disease.
Are not able to take drugs by mouth and cannot absorb them.
Have had pancreatitis or hepatitis within the previous 6 months.
Have a drug allergy or other allergy which might cause a problem during the study.
Have had radiation or chemotherapy within 28 days of taking the study drug, or expect to need these during the study.
Have taken drugs that affect the immune system (corticosteroids, interleukins, interferons) or drugs with anti-HIV activity (hydroxyurea or foscarnet) within 28 days prior to taking the study drug.
Have had any HIV vaccine within 3 months before taking the study drug.
Have taken certain other drugs within 28 days prior to taking the study drug, or expect to need them during the study.
Use alcohol or illicit drugs in a way that the doctor feels would interfere with the study.